Omesdafexor

Omesdafexor (MET642) is an oral FXR agonist. Omesdafexor can improve colitis induced by adoptive T cell transfer, promote intestinal antimicrobial function, barrier function and inhibit inflammation [1][2][3].

Product Specifications

CAS Number

[2244440-85-3]

Product Name Alternative

MET642

UNSPSC

12352005

Target

FXR

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/omesdafexor.html

Purity

99.65

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C=C1[C@@H](CC2)CC[C@H]2CN(C3=CC(C4=CN(C5CC5)N=C4)=CC=C3)C([C@@H]6CC[C@H](CC6)O)=O)=C(C=C1)OC

Molecular Formula

C34H43N3O3

Molecular Weight

541.72

References & Citations

[1]https://cdn.who.int/media/docs/default-source/international-nonproprietary-names- (inn) /pl127.pdf?sfvrsn=8544ca1e_3&download=true|[2]Xueqing Liu, et al. COMBINATION OF FXR AGONIST MET642 WITH TOFACITINIB EXHIBITS SYNERGISTIC EFFECTS IN IMPROVING COLITIS IN ADOPTIVE T-CELL TRANSFER IBD MODEL. METACRINE.|[3]Xueqing Liu, et al. P153 MET642, AN ORAL FXR AGONIST, IMPROVES COLITIS INDUCED BY ADOPTIVE T-CELL TRANSFER. Volume 158, Issue 3, Supplement S11February 2020.